XNK
is a Switzerland-based clinical-stage biotechnology company that researches and develops novel NK cell-based therapies for the treatment of cancer... Read moreXNK
is a Switzerland-based clinical-stage biotechnology company that researches and develops novel NK cell-based therapies for the treatment of cancer... Read more
News
Feb 08, 2024
FinanzNachrichten
XNK: XNK Therapeutics AB: XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event
Jan 16, 2024
Pharamceutical Technology
XNK: XNK Therapeutics' Evencaleucel gains EMA recommendation
Dec 04, 2023
FinanzNachrichten
XNK: XNK Therapeutics AB: XNK Therapeutics to present at DNB Nordic Healthcare Conference in Oslo
Nov 10, 2023
FinanzNachrichten
XNK: XNK Therapeutics AB: XNK Therapeutics to present at Investival Showcase Meeting
Nov 06, 2023
FinanzNachrichten
XNK: XNK Therapeutics AB: XNK Therapeutics announces poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Oct 10, 2023
FinanzNachrichten
XNK: XNK Therapeutics AB: XNK Therapeutics receives funding from Sweden's innovation agency Vinnova
Aug 26, 2023
Pharmabiz
XNK: XNK Therapeutics inks research collaboration with Karolinska University Hospital in acute myeloid leukaemia
Aug 24, 2023
Pharamceutical Technology
XNK: XNK partners with Swedish hospital to develop AML therapy
Aug 14, 2023
Cision
Press Release: XNK : XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September
Aug 14, 2023
FinanzNachrichten
XNK: XNK Therapeutics AB: XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September
